Iovance Biotherapeutics, Inc. IOVA
Set alert
As of Nov 3, 12:56 PM ET
- YTD
- +215.75%
- 1 year
- +342.05%
- Open
- 8.22
- Prev close
- 8.02
- Mkt cap
- 3.90B
- Vol
- 7.10M
- Avg vol
- 17.36M
- EPS
- -0.69
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.15
- High
- 8.74
- Forward P/E
- -40.97
- Beta
- 0.84
- Short ratio
- 3.26
- Inst. own
- 70.74%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 11.37
- 200-d avg
- 5.84
- 1y target
- 14.20
5D chart
Signals (114)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 12:25 PM | 31 minutes ago |
| SMA: Bearish | Nov 3, 12:20 PM | 36 minutes ago |
| SMA: Bullish | Nov 3, 11:50 AM | 1 hour ago |
| SMA: Bearish | Nov 3, 11:20 AM | 1 hour ago |
| RSI: Overbought | Nov 3, 11:10 AM | 1 hour ago |
| SMA: Bullish | Nov 3, 10:55 AM | 2 hours ago |
| MACD: Sell Signal | Nov 3, 10:55 AM | 2 hours ago |
| RSI: Overbought | Nov 3, 10:55 AM | 2 hours ago |
| SMA: Bearish | Nov 3, 10:50 AM | 2 hours ago |
| RSI: Overbought | Nov 3, 9:30 AM | 3 hours ago |
| SMA: Bullish | Nov 2, 3:45 PM | 21 hours ago |
| MACD: Buy Signal | Nov 2, 3:45 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 3:40 PM | 21 hours ago |
| MACD: Sell Signal | Nov 2, 3:35 PM | 21 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 2:45 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 2:35 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 2:15 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 2:10 PM | 22 hours ago |
| MACD: Buy Signal | Nov 2, 2:10 PM | 22 hours ago |
Newest 20 of 114.
News
-
1 hour ago benzinga.com
UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $8
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $7 to $8.
23 hours ago zacks.com
Iovance Gears Up to Report Q3 Earnings: Here's What to Expect
IOVA is poised for a Q3 earnings beat as Amtagvi sales drive revenue, Proleukin adds growth and pipeline progress draws investor attention.
4 days ago benzinga.com
Crude Oil Moves Lower; Caterpillar Shares Fall Following Q3 Results
U.S. stocks fell Thursday, led by a 9% Caterpillar drop; Porch, Teladoc and Crocs surged, while oil, gold and silver declined.
4 days ago seekingalpha.com
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript
5 days ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The company's market cap stands at $10.7 billion. The company's, Q3 earnings came out yesterday. Teladoc…
5 days ago marketbeat.com
Iovance's Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA Filing
Iovance Biotherapeutics NASDAQ: IOVA reported updated data from its registrational IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic non-small cell lung cancer, outlining…
5 days ago zacks.com
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 days ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
-
5 days ago benzinga.com
Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results
IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Supplemental Biologics License Application (sBLA) for Lifileucel in Non-Squamous mNSCLC in 2027KRAS Wild-Type Subgroup…
5 days ago globenewswire.com
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned…
5 days ago globenewswire.com
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026 PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on…
1 week ago zacks.com
Best Momentum Stocks to Buy for October 27th
IOVA, MEI and PRMRF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 27th, 2026.
1 week ago zacks.com
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
1 week ago zacks.com
New Strong Buy Stocks for October 27th
NTSK, PRMRF, IOVA, CAPL and MEI have been added to the Zacks Rank #1 (Strong Buy) List on October 27th, 2026.
1 week ago globenewswire.com
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal…
-
1 week ago benzinga.com
Iovance Biotherapeutics Reports Deep, Durable Responses With Lifileucel Monotherapy In Metastatic UPS And DDLPS At ESMO 2026
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026Unprecedented Efficacy in Both…
1 week ago globenewswire.com
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Unprecedented Efficacy in Both…
-
1 week ago benzinga.com
Iovance's Phase 2 Lifileucel Plus Pembrolizumab Delivers 62.5% ORR And 29.2% Complete Response Rate In Frontline Advanced Melanoma, With Median OS Not Yet Reached At 50.9 Months
62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 AnalysisMedian Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-upOral…
1 week ago globenewswire.com
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral…
2 weeks ago zacks.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
2 weeks ago globenewswire.com
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously…
2 weeks ago seekingalpha.com
Undercovered Dozen: Hess Midstream, Iovance Biotherapeutics, Netlist, And More
The Undercovered Dozen highlights 12 lesser-covered stocks from the past week on Seeking Alpha. This curated series aims to spark investment ideas and community discussion around overlooked equities.…
2 weeks ago globenewswire.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering…
-
3 weeks ago benzinga.com
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $15 to $18.
3 weeks ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
3 weeks ago benzinga.com
Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11
Baird analyst Colleen Kusy maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $6 to $11.
4 weeks ago benzinga.com
Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call
Iovance Biotherapeutics (NASDAQ:IOVA) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is…
4 weeks ago defenseworld.net
55,275 Shares of Iovance Biotherapeutics, Inc. $IOVA Purchased by Corient Private Wealth LP
Corient Private Wealth LP purchased a new stake in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) in the second quarter, according to its most recent disclosure with the Securities and Exchange…
4 weeks ago benzinga.com
Top 3 Health Care Stocks That May Collapse In Q4
Three healthcare stocks—Quantum-Si, Kodiak Sciences and Iovance—show overbought RSI readings above 80, warning momentum-focused investors.
4 weeks ago seekingalpha.com
Iovance: Buy Now Before Many Growth Catalysts Kick In
Iovance raised 2026 revenue guidance to $410–$420 million as Amtagvi adoption accelerates, supported by expanding treatment access, greater physician awareness, and faster manufacturing. Frontline…
1 month ago zacks.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
1 month ago globenewswire.com
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on…
-
1 month ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
1 month ago benzinga.com
Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18
Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $14 to $18.
1 month ago benzinga.com
Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?
Shares of Iovance Biotherapeutics are trading slightly lower Wednesday morning, taking a breather after Tuesday's surge which pushed the stock to a new 52-week high.
1 month ago benzinga.com
Fair Issac Corp., Iovance Biotherapeutics, Stablecoin Development Corp., Carnival Corp. and Micron: Why These 5 Stocks Are on Investors' Radars Today
FICO, IOVA, SDEV, CCL, MU were among the trending stocks on Tuesday, Sept. 29, 2026.
-
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago benzinga.com
Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars
Iovance Biotherapeutics upgrades 2026 revenue guidance to $410 million-$420 million. Key technicals, analyst targets, and Amtagvi demand analyzed.
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Stablecoin Development (AMEX:SDEV) stock increased by 121.6% to $3.48 during Tuesday's regular session. The market value of their outstanding shares is at $42.5 million. Iovance…
1 month ago benzinga.com
Crude Oil Down 1%; US Job Openings Fall In August
U.S. stocks fell as job openings declined; oil slid and gold rose. BKYI doubled, SSTI surged, while NIVF plunged 77% and QURE fell 37%.
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $20
HC Wainwright & Co. analyst Joseph Pantginis maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $9 to $20.
1 month ago benzinga.com
CarMax Posts Upbeat Q2 Earnings, Joins Iovance Biotherapeutics, Perella Weinberg Partners And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed as Dow fell 100+ points; CarMax surged 9.7% on strong results, while Iovance, Carnival and others gained.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock…
-
1 month ago benzinga.com
Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and announces $15 price target.
-
1 month ago benzinga.com
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $13 to $15.
2 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
2 months ago benzinga.com
TD Cowen Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $10
TD Cowen analyst Nicholas Lorusso maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $7 to $10.
2 months ago benzinga.com
Iovance Biotherapeutics Stock Is Trending Friday: What's Going On?
Shares of Iovance Biotherapeutics are trending Friday morning after a momentum surge pushed the biotech stock to a new 52-week high.
2 months ago benzinga.com
Why Iovance Biotherapeutics Stock Hit 52-Week High
Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amtagvi sales and analyst price target hikes.
-
2 months ago benzinga.com
UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $7
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $4 to $7.